Domann Recruits Gloria Matthews DVM, Ph.D. as Chief Medical Officer for Ankasa Regenerative Therapeutics, La Jolla, CA.

Ankasa is developing strategies to improve tissue healing by exploiting the potential of stem cell re-activation. Our initial product will be a proprietary formulation of WNT protein with demonstrated superiority for bone reformation over existing standards of care.

Dr. Matthews is a C-level executive helping great companies streamline their strategic approaches while rapidly and successfully developing Biologics. Decades of experience in end to end medical therapeutic, drug, device, biologics, and combination products. Excited to be building solid value at Ankasa Regenerative Therapeutics developing wnt3A for a multitude of indications.

Working at MiMedx Gloria lead efforts to transform a high growth public company from a tissue product distributor to a data-driven Biopharma company.

Recently Chief Medical Officer at Histogenics, a pre-revenue public regenerative medicine company directing Clinical, Medical Affairs, R&D, Regulatory, and Pharmacovigilance activities. Actively consulting on launch prep and early commercialization strategies, as well as securing corporate funding. Formerly Senior Director at one of the top 4 largest multinational pharmaceutical companies in the world with strategic responsibility for global R&D organization.
The successful development of this product will compete in a multi-billion dollar, and growing, market. The Company closed a syndicated Series A for $19MM and is lead by Sandy Madigan Chief Executive Officer.